Prioritizing Patient Rights in India’s Expanding Clinical Trials Landscape

In a country where clinical trials are becoming increasingly common, the importance of prioritizing patient rights has come to the forefront. One striking example is Ritu Bhalla, a 35-year-old woman who faced blood cancer diagnoses during her childhood. After enduring significant treatment, she was left with chronic hepatitis B. When she was approached in a Delhi hospital three years ago to participate in a gastrointestinal clinical trial, the encounter left her uneasy. The woman who approached her, presumably a trial coordinator, neither provided adequate information about the trial nor explained the purpose behind the blood sample request. Feeling uncomfortable and lacking clarity, Bhalla decided against participation.

Experts assert that Bhalla’s experience is not an isolated event but rather indicative of broader issues within the clinical trial framework in India. Although significant strides have been made since the Supreme Court’s intervention in 2013—resulting in enhanced regulatory measures aimed at protecting participants—the ethical treatment of individuals in trials remains a concern. Amendments to the Drugs & Cosmetics Rules have introduced crucial provisions, such as compensation for participants and requirements for video-recorded consent, particularly among vulnerable populations.

Poonam Bagai, founder and chairwoman of CanKids…KidsCan, emphasized the ongoing need for vigilance in safeguarding patient rights. The organization, which also oversees the Pediatric Cancer Research Institute (pCRI), has been a strong advocate for improved standards in clinical trials. With new regulations mandating the registration of ethics committees with the Central Drugs Standard Control Organization (CDSCO), the expectations for patient safety and informed consent are higher than ever.

Despite these advancements, the gap between policy and practice can still be significant. The need for proper training of trial coordinators and clarity in communication with participants is paramount. Individuals should be fully informed about the studies they are being asked to join, including potential risks and benefits. This transparency not only fosters trust but also empowers patients to make informed decisions regarding their participation in clinical research.

As India continues to emerge as a hub for clinical trials, the focus on patient rights needs to be unwavering. Ensuring that participants are treated ethically and are well-informed can enhance the integrity of clinical research in the country. The collective efforts of regulatory bodies, healthcare providers, and organizations like CanKids…KidsCan are crucial in fostering an environment where patient rights are not just acknowledged but prioritized.

Source: scroll.in